Abstract：
BACKGROUND:Natalizumab is a monoclonal antibody that significantly reduces the occurrence of relapses in relapse-remitting multiple sclerosis (RRMS) patients. Early papers on the clinical use of natalizumab in RRMS patients reported erythroblastemia as occasional and transient. OBJECTIVES:to determine the prevalence and absolute count of erythroblasts (nucleated red blood cells, NRBCs) in peripheral blood of RRMS patients in different treatment groups and healthy controls from the same geographic area using the same equipment for laboratory analysis. METHODS:We retrospectively evaluated the samples of 203 consecutive RRMS patients including 26 subjects on natalizumab, 17 on fingolimod, 72 on interferon, 41 on glatiramer acetate, 47 treatment-naïve and 240 healthy controls from the same geographic area. Blood samples were processed using an XN-9000-Hematology Analyzer and subsequent microscopic verification. In the natalizumab-treated patients we performed an additional analysis in order to detect the expression of CD34+ cells in peripheral blood, as confirmation of a bone marrow mobilization. RESULTS:The prevalence of patients with NRBCs positivity was significantly higher in natalizumab-treated patients (92%) compared with the other treatment groups and healthy controls (0%) (p<0.0005). The median absolute NRBCs count was significantly higher in natalizumab-treated patients (median 0.020, p<0.0005) than in the other treatment groups and healthy controls. Natalizumab-treated patients also had higher levels of white blood cells than all other groups and lower haemoglobin levels than healthy subjects (p<0.01), but no morphologic alterations were evident at a subsequent review of red blood cells, platelets and white blood cells. CD34+ cells levels were consistent with mobilization of haematopoietic stem cells from the bone marrow (median 8 cells/µL, IQR 5-12). CONCLUSIONS:We confirm erythroblastaemia as a frequent finding of natalizumab treatment in RRMS patients. More extended knowledge and adequate long-term observation of this phenomenon are essential to better understand any pathological implication.
journal_name
Mult Scler Relat Disordjournal_title
Multiple sclerosis and related disordersauthors
La Gioia S,Seghezzi M,Barcella V,Dominoni P,Mecca T,Frigeni B,Conti MZ,Vedovello M,Vidali M,Rottoli M,Buoro Sdoi
10.1016/j.msard.2016.05.020subject
Has Abstractpub_date
2016-07-01 00:00:00pages
141-4eissn
2211-0348issn
2211-0356pii
S2211-0348(16)30084-0journal_volume
8pub_type
杂志文章abstract：BACKGROUND:Olfactory dysfunction has been linked to clinical severity variables in multiple MS populations. Though, its prognostic value is still unknown. OBJECTIVE:The aim of this study was to explore the long-term outcome associated with Brief-Smell Identification Test (B-SIT) performance in a cohort of MS patients....
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102486
更新日期：2020-11-01 00:00:00
abstract：OBJECTIVES:To examine the association between vagotomy and multiple sclerosis. METHODS:We conducted a matched cohort study of all patients who underwent truncal or super-selective vagotomy and a comparison cohort, by linking Danish population-based medical registries (1977-1995). Hazard ratios (HRs) for multiple scler...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.04.009
更新日期：2017-07-01 00:00:00
abstract：:Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting multiple sclerosis (MS). It should be stopped at least two months before conception as it is not considered safe during pregnancy or when breast feeding. In vitro and animal studies have found a possibly increased risk of conge...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.02.015
更新日期：2018-04-01 00:00:00
abstract：:The clinical presentation of neurosarcoidosis is varied as multiple levels of the neuraxis may be affected. When central nervous system involvement occurs, making an accurate diagnosis of the condition can be challenging, especially given the current definition for definite neurosarcoidosis requires histologic confirm...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2015.06.012
更新日期：2015-09-01 00:00:00
abstract：OBJECTIVE:Using spectral domain optical coherence tomography (SD-OCT), to compare the choroidal thickness in a healthy population (group 1), with newly diagnosed multiple sclerosis (MS) patients (group 2), with MS patients who underwent β-interferon monotherapy (group 3) and MS patients who underwent fingolimod therapy...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.03.005
更新日期：2017-05-01 00:00:00
abstract：BACKGROUND:Olfactory dysfunction is a known clinical feature of multiple sclerosis (MS). Some studies have shown that odor identification impairment is an essential feature associated with cognitive function in MS. This study investigates the relationship between olfactory identification and the disease state, includin...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101507
更新日期：2020-02-01 00:00:00
abstract：BACKGROUND:Delayed multiple sclerosis (MS) diagnoses are not uncommon, an early diagnostic tool is urgently warranted. We aimed to develop an effective tool through electronic health records and machine learning techniques to early recognize MS patients from hospital visitors in China. METHODS:Two case sets were colle...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102632
更新日期：2020-11-18 00:00:00
abstract：BACKGROUND:Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladribine has shown efficacy at all stages of MS. Following withdrawal from...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.11.001
更新日期：2019-01-01 00:00:00
abstract：:Multiple sclerosis (MS) is the most common acquired demyelinating disorder of the central nervous system (CNS). Diagnosing MS can be very challenging owing to its variable clinical features and lack of specific tests. Magnetic resonance imaging (MRI) is a key measure in this process. Although white matter lesions on b...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2019.101452
更新日期：2020-01-01 00:00:00
abstract：:A long-term neurologic sequela arising from COVID-19 infection in multiple sclerosis (MS) patients could be related both to the increase of cytokines and the activation of NLRP3 inflammasome by the Sars-CoV2. These two mechanisms may cause a worsening of MS several months after the resolution of the infection. ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2020.102540
更新日期：2020-11-01 00:00:00
abstract：OBJECTIVE:No available assessment tool offers a brief and psychometrically sound way for clinicians to quantify assessment of MS in a typical office visit. The objective of this study was to develop a brief clinician-reported outcome measure of MS signs and symptoms to standardize and quantify assessments that occur du...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.06.024
更新日期：2019-10-01 00:00:00
abstract：BACKGROUND:Cognitive deficits, especially in attention, are common in persons with MS (PwMS) and are associated with clinically meaningful outcomes, such as work disability and lower quality of life (QOL). In this study, we aimed to determine whether Cogmed Working Memory Training (CWMT) improves attention/working memo...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2021.102770
更新日期：2021-01-17 00:00:00
abstract：:Despite having a high rate of occurrence, erythroblast appearance in peripheral blood may not be a recognized adverse effect of natalizumab (NTZ) treatment. Additionally, the time course and cause of erythroblast appearance remain unclear. We report two cases of multiple sclerosis wherein NTZ treatment led to erythrob...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.01.041
更新日期：2019-04-01 00:00:00
abstract：BACKGROUND:The 2015 criteria for diagnosing neuromyelitis optica spectrum disorder (NMOSD) have encouraged several groups across the world to report on their patients using these criteria. The disease typically manifests with severe relapses of optic neuritis, longitudinally extensive myelitis and/or brainstem syndrome...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.11.031
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:Multiple Sclerosis (MS) specialists routinely evaluate misdiagnosed patients, or patients incorrectly assigned a diagnosis of MS. Misdiagnosis has significant implications for patient morbidity and healthcare costs, yet its contemporary incidence is unknown. We examined the incidence of MS misdiagnosis in ne...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.01.048
更新日期：2019-05-01 00:00:00
abstract：BACKGROUND:To determine and compare comorbidity levels in the multiple sclerosis (MS) population in Poland using a matched cohort from the general population. METHODS:We compared our database (standardized medical histories and medical records) from a MS center at the Department of Neurology, Medical University of Bia...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102051
更新日期：2020-06-01 00:00:00
abstract：BACKGROUND:The prevalence of multiple sclerosis (MS) varies throughout the world, and available epidemiological data suggest a progressively increasing prevalence of MS in Spain. The objective of this study was to calculate MS prevalence in Health District III of the autonomous community of Murcia in Spain. METHODS:Th...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2016.06.003
更新日期：2016-09-01 00:00:00
abstract：BACKGROUND:Prediction of the course of multiple sclerosis (MS) was traditionally based on features close to onset. OBJECTIVE:To evaluate predictors of the individual risk of secondary progression (SP) identified at any time during relapsing-remitting MS. METHODS:We analysed a database comprising an untreated MS incid...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2014.04.004
更新日期：2014-09-01 00:00:00
abstract：BACKGROUND:Neuromyelitis optica spectrum disorders (NMOSD) typically lead to spastic paraparesis and spare the peripheral nervous system (PNS). CASE REPORT:Here, we describe an anti-aquaporin-4-seropositive NMOSD patient suffering from acute transverse myelitis with painful, flaccid paralysis and incontinence of urine...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.07.032
更新日期：2018-10-01 00:00:00
abstract：BACKGROUND:The association between routine laboratory findings, including cerebrospinal fluid biomarkers, and neurological outcomes in patients with multiple sclerosis (MS) has not been fully elucidated. In this study, we evaluated blood and cerebrospinal fluid (CSF) analysis results at diagnosis and before treatment i...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102382
更新日期：2020-10-01 00:00:00
abstract：BACKGROUND:Neuromyelitis Optica Spectrum Disorder (NMOSD), commonly characterized by affecting optic nerves and spinal cord can be regarded as one of uncommon diseases of the central nervous system. Although the evidence presented in the literature supports cognitive impairments, psychological aspects of the disease an...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102128
更新日期：2020-07-01 00:00:00
abstract：:Multiple Sclerosis (MS) is an autoimmune disease in which lymphocytes target putative myelin antigens in the CNS, causing inflammation and neurodegeneration. Fingolimod (FTY720) is an immunosuppressive drug used as a second line therapy for relapsing forms of MS due to its safety profile and good response to treatment...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.05.004
更新日期：2017-11-01 00:00:00
abstract：BACKGROUND:Cognitive impairment is highly prevalent in multiple sclerosis (MS). Due to the lack of specialized neuropsychological resources in many MS clinics, a brief cognitive monitoring tool that can be administered by other MS clinic staff is needed. BICAMS (Brief International Cognitive As-sessment for Multiple Sc...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101458
更新日期：2020-01-01 00:00:00
abstract：BACKGROUND:Fatigue, depression, and physical inactivity are common in multiple sclerosis (MS), but there is limited information on the bi-directional associations among those variables over a long period of time. OBJECTIVE:This study examined the hypothesis that fatigue and depression would predict change in physical ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2011.08.003
更新日期：2012-01-01 00:00:00
abstract：BACKGROUND:Little is known about the factors associated with the selection of Disease Modifying Agents (DMA) for the management of Multiple Sclerosis (MS) since the introduction of oral DMAs in 2010. OBJECTIVES:To examine the factors associated with initiation of oral DMAs in patients with MS using data from electroni...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102334
更新日期：2020-10-01 00:00:00
abstract：BACKGROUND:Fingolimod (Gilenya, Novartis, Basel Switzerland) 0.5 mg orally once-daily is widely used for relapsing-remitting multiple sclerosis. Patients are usually screened four months after starting fingolimod for fingolimod-associated macular oedema (FAME). Large registration trials with stringent eligibility crite...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102125
更新日期：2020-07-01 00:00:00
abstract：BACKGROUND:Aquaporin 4 (AQP4)- and myelin oligodendrocyte glycoprotein (MOG)-associated neuromyelitis optica spectrum disorders (NMOSD) are thought to primarily affect the central nervous system (CNS). However, emerging evidence suggests that there are extra-CNS manifestations of NMOSD, including myopathies, gastrointe...
journal_title：Multiple sclerosis and related disorders
pub_type：
doi：10.1016/j.msard.2020.102032
更新日期：2020-06-01 00:00:00
abstract：BACKGROUND:The presence of white mater lesions in the central nervous system forces the differential diagnosis between multiple sclerosis (MS) and Anderson-Fabry disease (FD). Due to the type of inheritance, linked to the X chromosome, the diagnosis of FD is especially difficult in women. Tissue´s deposits of globotria...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101466
更新日期：2020-02-01 00:00:00
abstract：INTRODUCTION:Interferon-beta (IFNβ) is currently the most used disease-modifying treatment for relapsing-remitting multiple sclerosis (RRMS), but it can lead to the production of neutralising antibodies (NABs) against IFNβ. CLINICAL CASE:A lady with a past history of genital herpes was diagnosed with RRMS, started IFN...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2014.11.007
更新日期：2015-01-01 00:00:00
abstract：:Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rat...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2015.04.005
更新日期：2015-07-01 00:00:00
